ABCL vs XENE Stock Comparison

ABCL currently leads XENE in this stock comparison, with AIQ scores of 64 vs 49. The clearest difference is momentum, while XENE has the stronger risk resilience profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 15 points
ABCL
Healthcare
vs
XENE
Healthcare
ABCL
AbCellera Biologics Inc.
Leads
Price
$11.49
Day move
-1.12%
AIQ Score
64/100
Best edge
Momentum
Sector
Healthcare
XENE
Xenon Pharmaceuticals Inc.
Price
$40.48
Day move
-1.26%
AIQ Score
49/100
Best edge
Risk Resilience
Sector
Healthcare

What is the main difference between ABCL and XENE?

ABCL leads the current stock comparison as AbCellera Biologics Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

AbCellera Biologics Inc. vs Xenon Pharmaceuticals Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 63/66 fields· High confidence
AIQ VerdictCompetitiveAIQ Comparison Conviction 7/10

ABCL leads

ABCL leads by 15 AIQ points, primarily on Momentum. Wall Street currently favors XENE on target upside.

Competitive: 3 of 5 evidence groups support ABCL, and its current signal state is conflicted.

Evidence agreement: 3 of 5Comparison trend: Stable
ABCL

AbCellera Biologics Inc.

Leads
AIQ Score
64/100
AIQ Edge Score
7/10
XENE

Xenon Pharmaceuticals Inc.

AIQ Score
49/100
AIQ Edge Score
8/10

The Algovestiq AIQ Score currently favors ABCL over XENE, 64 versus 49 as of Nov 15, 2026. ABCL's advantage is driven primarily by stronger momentum, while XENE holds the stronger risk resilience profile. ABCL also shows the weaker technical structure relative to its 50-day moving average, though analyst target upside currently favors XENE. 3 of 5 covered evidence groups favor ABCL today, and the comparison is rated Competitive on stability: the leader is throwing conflicting signals. ABCL lead: Stable — the AIQ differential has held near 15 points over 30 sessions.

Compare AbCellera Biologics Inc. and Xenon Pharmaceuticals Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

ABCL
-22.5%
XENE
+32.2%

Price return comparison

Growth of $10,000, price only

ABCL $7,753 · XENE $13,216

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare ABCL and XENE against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

ABCL advantage
0
XENE advantage
  • Momentum89 vs 33
    ABCL +56
  • Risk Resilience34 vs 49
    XENE +15
  • Quality61 vs 68
    XENE +7

3 of 5 evidence groups favor ABCL. ABCL’s edge is concentrated in momentum; XENE keeps a meaningful risk resilience edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

ABCL+1 AIQ

Largest factor move: Momentum +2

No signal started or stopped since the prior session; its 4 active signals are unchanged.

XENE0 AIQ

Largest factor move: Quality +1, not enough on its own to move the overall score.

New signals

  • ADX Trend Weakening — neutral, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.47x)

ABCL's lead widened by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — ABCL and XENE both carry a full feed there.

The central trade-off

ABCL (AbCellera Biologics Inc.): the stronger current systematic profile, led by momentum.

XENE (Xenon Pharmaceuticals Inc.): the counter-case, on risk resilience, quality, analyst expectations.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

ABCL

ABCL on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

ABCL

ABCL on combined revenue and EPS growth.

Value

Even

The two are level on Value.

Momentum

ABCL

ABCL on the Momentum factor, by 56 points.

Lower downside

XENE

XENE on Risk Resilience, by 15 points.

Analyst upside

XENE

XENE on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors ABCL, analyst targets favor XENE. That disagreement is the most useful thing on this page.

MeasureABCLXENENote
Implied upside to target+50.9%+67.6%XENE has more room
Target dispersion+46.2%+64.8%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering1318Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

3 of 5 covered evidence groups favor ABCL. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreABCL64 vs 49
FundamentalsABCLTTM ROE -3.8% vs -9.6%
ValuationNot coveredNot covered
TechnicalsABCLPrice vs 50-day -6.9% vs -1.6%; vs 200-day 58.8% vs -22.6%
Risk ResilienceXENERisk Resilience 34 vs 49
Analyst expectationsXENETarget upside 50.9% vs 67.6%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of ABCL and XENE and are excluded from the count.

AIQ Decision Stability

Competitive

The two are close enough that your objective, not the score, should decide.

  • The AIQ gap is wide at 15 points. (supports the conclusion holding)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ABCL.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

ABCL lead: Stable — the AIQ differential has held near 15 points over 30 sessions.

May 27ABCL leads above the line · XENE leads belowNov 13
Today
ABCL +15
64 vs 49
7 sessions ago
ABCL +13
62 vs 49
30 sessions ago
ABCL +16
62 vs 46
90 sessions ago
XENE +9
64 vs 73

The lead changed hands once in this window, most recently on Sep 18 when ABCL moved ahead of XENE.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

ABCLConflicted

1 bullish / 2 bearish / 1 neutral, conflicted

Only ABCL

  • Golden Cross Active — bullish, trend, long horizon (70.46%)
  • Beta Spike Warning — bearish, risk_regime, long horizon
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
XENE

0 bullish / 3 bearish / 2 neutral

Only XENE

  • Death Cross Active — bearish, trend, long horizon (27.10%)
  • ADX Trend Weakening — neutral, trend, medium horizon
  • Downtrend Structure Active — bearish, trend, long horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.47x)

Both carry 1 more signal that do not separate them: ATR Expansion - Breakout Mode.

ABCL leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

ABCLDivergence

Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -1.12%, AIQ +1 points).

XENENo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.26%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1XENE closes the Momentum gap — currently 56 points behind, the largest single contributor to ABCL's edge.
  2. 2XENE's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3ABCL's conflicting signal state resolves bearish — it currently carries 1 bullish and 2 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

ABCL leads on balance
MetricABCLXENE
Revenue growth (YoY)162.7%0%
EPS growth (YoY)27.8%0%
Gross margin75.6%0%
Operating margin-298%0%
Return on equity (TTM)-3.8%-9.6%
Debt to equity0.130.01

Performance

ABCL leads 4 of 6 windows
MetricABCLXENE
1 week (5 sessions)-3.3%3.3%
1 month (20 sessions)-2.6%20.9%
3 months (63 sessions)2.6%-35.1%
6 months (126 sessions)180.9%-25.6%
Year to date236%-9.7%
1 year (252 sessions)189.4%2%

Technicals

ABCL has the stronger structure
MetricABCLXENE
RSI (14)45.254.9
ADX (14)11.924
Price vs 50-day-6.9%-1.6%
Price vs 200-day58.8%-22.6%
Volatility (1M, annualized)88.8%38%

Risk

XENE is the more resilient
MetricABCLXENE
Beta2.420.86
Sharpe ratio1.730.27
Sortino ratio3.020.48
Max drawdown-40.1%-52.8%
Current drawdown-22.5%-43%
Annualized volatility85.3%68.1%
Value at risk (95%)-7.1%-3.3%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, ABCL or XENE?

On the Algovestiq AIQ Score, ABCL is the stronger of the two as of Nov 15, 2026, scoring 64 against XENE's 49. The edge comes from momentum. XENE is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is ABCL or XENE the better buy right now?

ABCL carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Competitive — 3 of 5 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.

Why does the AIQ Score favor ABCL over XENE?

The composite weights Quality, Value, Momentum and Risk Resilience. ABCL leads Momentum by 56 points; XENE leads Risk Resilience by 15 points; XENE leads Quality by 7 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, ABCL or XENE?

Analyst price targets imply +50.9% upside for ABCL and +67.6% for XENE, so the Street currently favors XENE. That points the opposite way to the AIQ Score, which favors ABCL. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, ABCL or XENE?

Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, ABCL or XENE?

ABCL on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, ABCL or XENE?

ABCL on the Momentum factor, by 56 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, ABCL or XENE?

XENE is the more resilient of the two, so the other name carries the higher downside risk. XENE on Risk Resilience, by 15 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is ABCL more profitable than XENE?

ABCL leads on the comparable margin measures — gross margin 75.6% vs 0%; operating margin -298% vs 0%; ttm roe -3.8% vs -9.6%.

Is ABCL's lead over XENE getting stronger or weaker?

ABCL lead: Stable — the AIQ differential has held near 15 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands once in that window, most recently on 2026-09-18, when ABCL moved ahead of XENE.

What would change the ABCL vs XENE verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: XENE closes the Momentum gap — currently 56 points behind, the largest single contributor to ABCL's edge; XENE's Death Cross Active resolves — a bearish trend rule currently active against it; ABCL's conflicting signal state resolves bearish — it currently carries 1 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about ABCL and XENE?

ABCL: 1 bullish / 2 bearish / 1 neutral, conflicted. XENE: 0 bullish / 3 bearish / 2 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on ABCL is Golden Cross Active (bullish, long horizon). On XENE it is Death Cross Active (bearish, long horizon).

Compare ABCL and XENE with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.